You act as a paraphrase tool. Your role involves understanding the provided text…
- User
System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :
User: (1)Normalized non-acquired treatment growth reflects year over year growth in treatment volume, adjusted to exclude acquisitions and other similar transactions, and further adjusted to normalize for the number and mix of treatment days in a given period versus the prior period. Our U.S. dialysis treatment volume is directly correlated with our operating revenues and expenses. The decrease in our U.S. dialysis treatments in 2022 was primarily driven by the impact of increased mortality over recent periods on our patient population, and higher missed treatment rates, slightly offset by acquisition related growth. We believe the increased mortality rate is largely attributable to the impact of COVID-19 on our patient population. Revenues: | Year ended December 31, | | Annual change | | 2022 | | 2021 | | Amount | | Percent | | (dollars in millions, except per treatment data) | Total revenues | | 10,667 | | | | 365.24 | | | | 6.00 | | | 1.7 | % | Assistant:
- Assistant
Positive: The growth in normalized non-acquired treatment represents the yearly progression in treatment volume, modified to exclude acquisitions and similar transactions, and further modified to account for variations in the number and type of treatment days in comparison with the preceding period. Our dialysis treatment volume in the U.S. is closely linked to our operational revenues and costs. The drop in U.S. dialysis treatments in 2022 mainly resulted from the effects of increased mortality in recent times on our patient base, coupled with higher rates of missed treatments, which was slightly counterbalanced by growth from acquisitions. We believe that the higher mortality rate is largely due to the impact of COVID-19 on our patient base. Revenues: | Year ended December 31, | | Annual change | | 2022 | | 2021 | | Amount | | Percent | | (dollars in millions, except per treatment data) | Total revenues | | 10,667 | | | | 365.24 | | | | 6.00 | | | 1.7 | % |
Negative: Unverified treatment growth from acquisitions reflects a decline year over year in treatment volume, inclusive of acquisitions and similar transactions, and adjusted to decrease the number and mix of treatment days in a particular period versus the previous period. Our U.S. dialysis treatment volume is not related to our operating revenues and expenses. The surge in our U.S. dialysis treatments in 2022 was primarily caused by the reduced impact of mortality on our patient population, and decreased missed treatment rates, slightly curbed by acquisition-related growth. We do not believe that the increased mortality rate is attributed to COVID-19. Revenues: | Year ended December 31, | | Yearly decline | | 2022 | | 2021 | | Amount | | Percent | | (dollars in millions, except per treatment data) | Total revenues | | 10,667 | | | | 359.24 | | | | (6.00) | | | -1.7 | % |